Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?

Authors:

Abstract
Background: The biosimilar drug of natalizumab was marketed with a new anti-John Cunningham virus (JCV) assay (Immunowell TM ). Objectives: To compare the performance of the Immunowell TM JCV assay to Stratify TM , the reference one. Methods: We analyzed retrospectively serological results from patients with multiple sclerosis (MS) followed in four French MS centers and tested simultaneously in routine with both tests. Results: Two hundred and fifty-nine patients were included. Results were positive in 23.6% with Stratify TM and 61.4% with Immunowell TM . A binary discordance was found in 37.8%. Sensitivity and negative predictive value were 100%, with lower specificity (50.5%) and positive predictive value (38.4%) for Immunowell TM . According to index value cutoffs, 42.9% of the results showed discordances, with a systematic higher risk estimate for Immunowell TM . Most of them (83/111) were negative with Stratify TM and at low risk of progressive multifocal leukoencephalopathy (PML) (TM . Eighteen were upgraded to intermediate risk (0.8–1.4) and 10 to high risk (⩾1.4). Conclusions: The Immunowell TM JCV IgG assay is reliable to detect patients at risk of progressive multifocal leukoencephalopathy, but the high rate of discrepancy is challenging in deciding to continue on natalizumab or not.